Kura Oncology Inc (KURA)
$10.20 -$0.04 (-0.39%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$829.74M -
Day's Range
$10.14 - $10.50 -
Volume
3,629,304 -
52 Week Low / High
$9.68 - $24.17 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 11
- Strong Buy
- 3
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong Sell
- $29.88
- Target Price
Company News
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024
Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024
Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024
Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024
Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024
Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024
Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...
-
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024
Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...
-
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024
Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...
Similar Stocks
Portfolio
Comprised of 1 portfolios